Ambalal Sarabhai Enterprises Ltd (AMBALALSA) is currently trading at 34.51 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ambalal Sarabhai Enterprises Limited is an Indian diversified pharmaceutical and healthcare company that manufactures bulk drugs, finished formulations, molecular diagnostics and electronic instruments through group companies and subsidiaries, with a strategic portfolio focused on oncology, fertility, women’s healthcare and selected specialty therapeutic segments in domestic and international markets. Q1 FY2026 consolidated results show Total Income of INR 4,559.02 lakhs versus INR 4,205.04 lakhs year‑ago (about 8.4% growth), EBITDA rose to INR 657.07 lakhs from INR 319.21 lakhs (≈106% increase) and PBT improved to INR 467.86 lakhs from INR 128.73 lakhs, indicating meaningful margin recovery and profitability improvement on a small absolute base. Operationally, Ambalal Sarabhai Enterprises Limited has scaled up its Ranoli oncology and synthetic API facility in 2026 after commissioning the plant in 2023, representing a substantive manufacturing ramp that should expand production capacity for oncology APIs and formulations and improve revenue visibility through higher utilization. The company’s history of technical collaborations and joint ventures (Biobras, Chiron, Sarabhai Piramal JV) and prior acquisitions (Suvik Hitek, Systronics) reflects a legacy of product and capability augmentation; combined with recent investments, this shows strategic intent to sustain a presence in niche therapeutic and diagnostic segments. Despite strong quarter-on-quarter margin expansion, Ambalal Sarabhai Enterprises Limited remains modest in absolute scale relative to large Indian pharmaceutical peers, implying higher sensitivity to project-level risks, market concentration in specialty areas, and the need to convert capacity expansion into consistent top-line growth.

Over the past 52 weeks, Ambalal Sarabhai Enterprises Ltd has traded between a low of ₹23.12 and a high of ₹49.98. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ambalal Sarabhai Enterprises Ltd has a market capitalization of approximately 265.15. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ambalal Sarabhai Enterprises Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 265.15 Cr, Ambalal Sarabhai Enterprises Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ambalal Sarabhai Enterprises Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ambalal Sarabhai Enterprises Ltd is 19.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.